Delaware | 1-3619 | 13-5315170 |
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
235 East 42nd Street New York, New York (Address of principal executive offices) | 10017 (Zip Code) |
Item 5.07 | Submission of Matters to a Vote of Security Holders | |||||
(a) The Pfizer Inc. (the "Company") Annual Meeting of Shareholders was held on April 25, 2019. | ||||||
(b) Shareholders voted on the matters set forth below. | ||||||
1. The nominees for election to the Company’s Board of Directors were elected to hold office until the Company’s next Annual Meeting of Shareholders, based upon the following votes: | ||||||
Nominee | Votes For | Votes Against | Abstentions | Broker non-vote | ||
Ronald E. Blaylock | 3,912,479,252 | 78,594,255 | 11,037,194 | 887,836,749 | ||
Albert Bourla | 3,968,299,845 | 23,724,642 | 10,086,214 | 887,836,749 | ||
W. Don Cornwell | 3,792,127,947 | 199,713,095 | 10,264,240 | 887,836,749 | ||
Joseph J. Echevarria | 3,824,294,719 | 167,540,269 | 10,276,108 | 887,836,749 | ||
Helen H. Hobbs | 3,960,013,945 | 33,120,500 | 8,974,658 | 887,836,749 | ||
James M. Kilts | 3,856,874,668 | 135,060,973 | 10,175,455 | 887,836,749 | ||
Dan R. Littman | 3,959,418,600 | 32,811,206 | 9,881,290 | 887,836,749 | ||
Shantanu Narayen | 3,948,229,994 | 43,833,811 | 10,047,291 | 887,836,749 | ||
Suzanne Nora Johnson | 3,878,704,857 | 114,112,491 | 9,293,748 | 887,836,749 | ||
Ian C. Read | 3,948,620,315 | 41,924,275 | 11,566,505 | 887,836,749 | ||
James C. Smith | 3,941,173,326 | 50,720,278 | 10,217,492 | 887,836,749 |
2. The proposal to ratify the selection of KPMG LLP as the Company’s independent registered public accounting firm for the 2019 fiscal year was approved based upon the following votes: | |||
Votes for approval | 4,701,180,439 | ||
Votes against | 175,867,847 | ||
Abstentions | 12,887,303 | ||
Broker non-votes | n/a | ||
3. The proposal to approve, on an advisory basis, the compensation of the Company's Named Executive Officers was approved based upon the following votes: | |||
Votes for approval | 3,764,667,463 | ||
Votes against | 200,933,424 | ||
Abstentions | 36,509,563 | ||
Broker non-votes | 887,836,749 | ||
4. The proposal to approve the Pfizer Inc. 2019 Stock Plan was approved based upon the following votes: | |||
Votes for approval | 3,439,109,067 | ||
Votes against | 540,573,214 | ||
Abstentions (Have the same effect as a vote against this proposal under New York Stock Exchange rules) | 22,428,815 | ||
Broker non-votes | 887,836,749 | ||
5. The shareholder proposal regarding right to act by written consent was not approved based upon the following votes: | |||
Votes for approval | 494,345,288 | ||
Votes against | 3,478,617,639 | ||
Abstentions | 29,142,088 | ||
Broker non-votes | 887,836,749 | ||
6. The shareholder proposal regarding report on lobbying activities was not approved based upon the following votes: | |||
Votes for approval | 1,179,442,668 | ||
Votes against | 2,780,664,931 | ||
Abstentions | 42,003,373 | ||
Broker non-votes | 887,836,749 | ||
7. The shareholder proposal regarding independent chair policy was not approved based upon the following votes: | ||||
Votes for approval | 1,067,318,698 | |||
Votes against | 2,909,751,046 | |||
Abstentions | 25,039,598 | |||
Broker non-votes | 887,836,749 | |||
8. The shareholder proposal regarding integrating drug pricing into executive compensation policies and programs was not approved based upon the following votes: | ||||
Votes for approval | 1,132,357,518 | |||
Votes against | 2,814,700,448 | |||
Abstentions | 55,053,129 | |||
Broker non-votes | 887,836,749 | |||
(c) Not applicable | ||||
(d) Not applicable |
PFIZER INC. | ||
Dated: April 29, 2019 | By: /s/ Margaret M. Madden Margaret M. Madden | |
Title: Senior Vice President & Corporate Secretary Chief Governance Counsel |